Previous Close | 2.8650 |
Open | 2.8980 |
Bid | 2.8680 x N/A |
Ask | 3.0040 x N/A |
Day's Range | 2.8660 - 2.9090 |
52 Week Range | 2.8660 - 2.9090 |
Volume | |
Avg. Volume | N/A |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.
Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial SolutionsMORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fosun Pharma USA Inc. (“Fosun Pharma USA“), the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK). As part of the partnership, Syneos Healt
Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab in the United States (US). This marks an important milestone for Fosun Pharma's development in the US.